Anaplastic Lymphoma Kinase Positive, Advanced Non-Small Cell Lung Cancer - 2020 Pipeline Landscape Overview - ResearchAndMarkets.com

DUBLIN--()--The "Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) market.

A detailed picture of the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) pipeline landscape is provided, which includes the disease overview and Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) treatment guidelines.

The assessment part of the report embraces in-depth Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) commercial assessment and clinical assessment of the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) treatment.
  • Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) market.

Scope of the Report

  • The Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Anaplastic Lymphoma Kinase (ALK) Positive, Advanced Non-Small Cell Lung Cancer (NSCLC).

Companies Mentioned

  • Hoffmann-La Roche
  • Ariad Pharmaceuticals
  • Takeda
  • Pfizer
  • Synta Pharmaceuticals Corp.
  • Xcovery Holding Company, LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w7ru9z

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900